Vesugen
Also known as: Lys-Glu-Asp, Vascular bioregulator
Vesugen (also called Lys-Glu-Asp or Vascular bioregulator) is a khavinson vascular tripeptide in the Short Peptide Bioregulator class. Vesugen is Lys-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with vascular tissue.
For research use only.
Key Facts
- CAS
- 204271-66-9
- Molecular Weight (MW)
- ≈390.4 g/mol
- Half-life
- Not established (limited public PK data; primarily research context)
- FDA status
- Not Approved
- Administration Route
- Oral or sublingual (common commercial formats); injectable research use exists by supplier
- Frequency
- Once daily (typical research pattern)
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Vascular endothelium (proposed)
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected between Dec 2025 and Feb 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 2
- Listed offers
- 2
- Price per mg
- $3.00–$3.25/mg
Research summary
Lys-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series associated with vascular tissue and endothelial function. It is distinct from Ventfort, the tissue extract marketed for the same purpose. The proposed activity rests on cell-culture and cytogenetic work from one research group published mainly in Russian, without independent replication or controlled human evidence. Not FDA-approved.
Peptide Library's Vesugen profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- 5-20 mg daily (research context; not clinically established)
- Frequency
- Once daily (typical research pattern)
- Cycle
- 10-30 days common in bioregulator protocols (research context)
- Administration Route
- Oral or sublingual (common commercial formats); injectable research use exists by supplier
- Reconstitution Guide
- If lyophilized: reconstitute with bacteriostatic water per lab SOP (research only)
- Injection Sites
- Abdomen (subQ)
- Concentration Example
- 20 mg vial reconstituted with 2 mL = 10 mg/mL
- Timing Notes
- Often administered in the morning; consistency is emphasized in bioregulator protocols
- Expected Onset
- Variable; proposed cellular signaling effects over weeks
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Vesugen is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Amino acid sequence | Lys Glu Asp (KED) |
|---|---|
| Molecular formula | C15H26N4O8 |
| Molecular weight | ≈390.4 g/mol |
| CAS number | 204271-66-9 |
| Half-life | Not established (limited public PK data; primarily research context) |
| Appearance | White lyophilized powder or tablets (supplier dependent) |
| Formulation | Lyophilized Powder |
| PubChem CID | 87571363 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Vesugen is Lys-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with vascular tissue. The series hypothesis proposes that such peptides enter the nucleus and interact with specific promoter sequences to influence transcription of tissue-relevant genes, with reported effects here on endothelial cell protein synthesis and vascular wall markers. The evidence consists of cell-culture and cytogenetic studies from one research group published mainly in Russian; there is no independent replication, no characterised receptor, and no modern randomised controlled trial evidence for vascular outcomes.
Origin
Synthetic short peptide.
Targets
Studies
- [Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.]
- Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds
- [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)]
- Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells
- Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease
Regulatory & research status
Vesugen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Vesugen side effects
Side Effects
- Not characterized
Stacking
Common stacking partners
Combinations that include Vesugen, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Vesugen: frequently asked questions
What is Vesugen?
Lys-Glu-Asp, a synthetic tripeptide in the Khavinson bioregulator series associated with vascular tissue and endothelial function. It is distinct from Ventfort, the tissue extract marketed for the same purpose. The proposed activity rests on cell-culture and cytogenetic work from one research group published mainly in Russian, without independent replication or controlled human evidence. Not FDA-approved.
How does Vesugen work?
Vesugen is Lys-Glu-Asp, a synthetic tripeptide in the Khavinson series associated with vascular tissue. The series hypothesis proposes that such peptides enter the nucleus and interact with specific promoter sequences to influence transcription of tissue-relevant genes, with reported effects here on endothelial cell protein synthesis and vascular wall markers.
Is Vesugen FDA approved?
No. Vesugen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Vesugen?
Reported half-life for Vesugen is Not established (limited public PK data; primarily research context). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Vesugen?
Vesugen has the sequence Lys Glu Asp (KED). Its molecular formula is C15H26N4O8.
What peptides are similar to Vesugen?
Compounds most often compared with Vesugen include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.] — Adv Gerontol, 2024External reference
- Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds — Bull Exp Biol Med, 2013External reference
- [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)] — Georgian Med News, 2012External reference
- Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells — Bull Exp Biol Med, 2012External reference
- Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease — Bull Exp Biol Med, 2021External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 2
This Vesugen profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Vesugen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →